Affymetrix, Inc. (NASDAQ:AFFX) today announced a research collaboration and licensing agreement with Massachusetts General Hospital (MGH) to co-develop new cancer biomarker tests using the Affymetrix’ QuantiGene® ViewRNA Assay platform*, an in situ hybridization assay capable of single transcript in single-cell detection. As part of this agreement, Affymetrix has the rights to commercialize the new biomarker tests as an outcome of this collaboration.
“This agreement provides Affymetrix with an important opportunity to expand its QuantiGene ViewRNA Assay offering into the pathology and cancer research markets by providing new multiplex chromogenic in situ hybridization (CISH) and fluorescence in situ hybridization (FISH) RNA biomarker assays which are validated on clinical samples for research applications. Advanced in situ RNA hybridization methods applied to less invasive clinical samples such as FFPE core biopsies, FNAs, and CTCs has the potential of becoming powerful new tools to deliver diagnostics that enable the oncologist to personalize patient care,” stated George Bers, Vice President and General Manager, Gene Expression Business Unit Manager – Panomics at Affymetrix.
Currently, those who practice surgical pathology and cytology face challenges in the management of a broad range of cancers. Medical practitioners are optimistic that a solution to these challenges will be found in new biomarkers and drug targets which are being rapidly discovered by NGS and microarray technologies. Yet these new biomarker discoveries have in themselves become a challenge requiring extensive validation prior to becoming candidates for translation into diagnostic, prognostic, and predictive tests to fulfill the promise of delivering a new generation of personalized medicine and associated economic and healthcare outcomes.
"The future of cancer treatment lies in our ability to precisely identify specific biomarkers so we can then find effective drugs for that particular form of disease,” said Daniel A. Haber, MD, PhD, director of the MGH Cancer Center. “This collaboration with Affymetrix aims to move this important work forward."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV